Scientific work

Doç. Dr. Aysun Şentürk Yıkılmaz

94 publications. The source of the information is stated next to each publication.

Back to profile

  1. Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study

    Journal of Thrombosis and Thrombolysis, 2026

    DOI 10.1007/s11239-026-03363-8 PMID 42565930 Open-access full textSource: OpenAlex

  2. Original Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020634 PMID 41598573 Open-access full textSource: ORCID

  3. (PB2953) REAL-WORLD EFFICACY AND CARDIOVASCULAR SAFETY OF ACALABRUTINIB IN B-CELL MALIGNANCIES: A TURKISH MULTICENTER EXPERIENCE COMPARING FRONTLINE INITIATION VS. TRANSITION AFTER IBRUTINIB INTOLERANCE Topic: 06. Chronic lymphocytic leukemia and related disorders -Clinical

    2026

    DOI 10.13140/rg.2.2.20277.44000 Source: OpenAlex

  4. Real-World Outcomes of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia Patients: A Multicenter Comparison of the Use of Fluconazole and Micafungin

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207294 PMID 41156164 Open-access full textSource: OpenAlex

  5. Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14196813 PMID 41095893 Open-access full textSource: OpenAlex

  6. MİYELOPROLİFERATİF NEOPLAZMLARDA SPLANKNİK VEN TROMBOZUNUN DEĞERLENDİRİLMESİ: THD KRONİK MİYELOSİTER LÖSEMİ VE KRONİK MİYELOPROLİFERATİF NEOPLAZMLAR VE HEMOSTAZ - TROMBOZ BİLİMSEL ALT KOMİTELERİ ÇOK MERKEZ ÇALIŞMASI

    Bursa Uludag University - AVESIS, 2025

    Source: OpenAlex

  7. MİYELOPROLİFERATİF NEOPLAZMLARDA SPLANKNİK VEN TROMBOZUNUN DEĞERLENDİRİLMESİ: THD KRONİK MİYELOSİTER LÖSEMİ VE KRONİK MİYELOPROLİFERATİF NEOPLAZMLAR VE HEMOSTAZ - TROMBOZ BİLİMSEL ALT KOMİTELERİ ÇOK MERKEZ ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Source: OpenAlex

  8. Revisiting morbidities and predictors in transfusion-dependent thalassemia: A cohort study over 10 years from the national registry of hemoglobinopathies in Türkiye

    Blood, 2025

    DOI 10.1182/blood-2025-4690 Source: OpenAlex

  9. A Rare But Fatal Toxicity: Immune Checkpoint Inhibitor–Related Acquired Thrombotic Thrombocytopenic Purpura

    Journal of Immunotherapy and Precision Oncology, 2025

    DOI 10.36401/jipo-24-2 PMID 39811422 1 citation (Europe PMC) Open-access full textSource: ORCID

  10. Real-World Outcomes of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia: A Multicenter Comparison of Fluconazole and Micafungin

    2025

    DOI 10.20944/preprints202509.0283.v1 Open-access full textSource: ORCID

  11. Morbidities in β-thalassemia intermedia across the spectrum of disease severity: A nationwide study in Türkiye

    Blood, 2025

    DOI 10.1182/blood-2025-1138 Open-access full textSource: OpenAlex

  12. Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group

    Medicina, 2024

    DOI 10.3390/medicina60101623 PMID 39459410 Open-access full textSource: ORCID

  13. Comparison of low dose cytosine arabinoside, azacitidine and azacitidine venetoclax combination treatment as remission induction in elderly acute myeloid leukemia patients

    Journal of Medicine and Palliative Care, 2023

    DOI 10.47582/jompac.1365715 Open-access full textSource: ORCID

  14. Learning From Failure: Negative Trials in Oncology

    Journal of Immunotherapy and Precision Oncology, 2023

    DOI 10.36401/jipo-23-x1 PMID 37214208 4 citations (OpenAlex) Open-access full textSource: OpenAlex

  15. Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia

    International Journal of Hematology-Oncology and Stem Cell Research, 2023

    DOI 10.18502/ijhoscr.v17i1.11712 PMID 37638287 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  16. Multiple Myeloma ve Plazma Hücreli Neoplaziler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1210 Source: OpenAlex

  17. Hematolojide Güncel Yaklaşımlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1547 Open-access full textSource: OpenAlex

  18. IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY

    Mediterranean Journal of Hematology and Infectious Diseases, 2022

    DOI 10.4084/mjhid.2022.074 PMID 36425152 6 citations (Europe PMC) Open-access full textSource: ORCID

  19. Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

    Blood, 2022

    DOI 10.1182/blood-2022-169319 1 citation (OpenAlex) Source: ORCID

  20. Kronik Lenfositik Lösemi

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1209 Open-access full textSource: OpenAlex

  21. Evaluation of Bone Mineral Densitometry Measurements in Patients with BCR/ABL-Negative Chronic Myeloproliferative Neoplasm

    Acta Oncologica Turcica, 2021

    DOI 10.5505/aot.2021.72324 Open-access full textSource: OpenAlex

  22. Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.

    The Malaysian journal of medical sciences : MJMS, 2020

    DOI 10.21315/mjms2020.27.1.7 PMID 32158346 Open-access full textSource: ORCID

  23. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.

    Clinical Lymphoma, Myeloma & Leukemia, 2020

    DOI 10.1016/j.clml.2019.11.021 PMID 32295735 10 citations (Europe PMC) Source: ORCID

  24. Does the platelet‑to‑lymphocyte ratio have a prognostic effect in patients with myelodysplastic syndrome?

    Bratislavske lekarske listy, 2020

    DOI 10.4149/bll_2020_068 PMID 32484706 3 citations (Europe PMC) Open-access full textSource: ORCID

  25. VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience

    International Journal of Hematology-Oncology and Stem Cell Research, 2020

    DOI 10.18502/ijhoscr.v14i4.4481 PMID 33603986 2 citations (Europe PMC) Open-access full textSource: ORCID

  26. Thiol – Disulphide Homeostasis in Polycythemia Vera

    Dicle Medical Journal / Dicle Tip Dergisi, 2019

    DOI 10.5798/dicletip.574893 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  27. Thiol-disulphide homeostasis in essential thrombocythemia patients

    Journal of Medical Biochemistry, 2019

    DOI 10.2478/jomb-2018-0045 PMID 31496912 7 citations (OpenAlex) Open-access full textSource: OpenAlex

  28. Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2019

    DOI 10.1007/s12288-019-01169-8 PMID 32158089 Open-access full textSource: ORCID

  29. In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2019

    DOI 10.1016/j.tracli.2019.07.005 PMID 31420221 1 citation (Europe PMC) Source: ORCID

  30. Effect of Treatment on the Muscle Mass and Response to Therapy in Hodgkin’s Lymphoma

    LLM Dergi, 2019

    DOI 10.5578/llm.67997 Open-access full textSource: ORCID

  31. Single-center experience: comparison of reduced intensive chemotherapy and low-dose cytarabine treatment as remission induction in older age aml cases

    Leukemia Research, 2019

    DOI 10.1016/s0145-2126(19)30302-9 Source: ORCID

  32. PB1886 THE TRANSMEMBRANE RECEPTOR TYROSINE KINASE‐LIKE ORPHAN RECEPTOR 1 IN CHRONIC LYMPHOCYTIC LEUKEMIA

    HemaSphere, 2019

    DOI 10.1097/01.hs9.0000566048.83902.ed Open-access full textSource: OpenAlex

  33. PB2171 THE COMPARISON OF THE RELATIONSHIP BETWEEN POLYNEUROPATHY FREQUENCY AND CLINICAL AND LABORATORY FINDINGS IN MULTIPLE MYELOMA CASES

    HemaSphere, 2019

    DOI 10.1097/01.hs9.0000567164.14031.93 Open-access full textSource: OpenAlex

  34. Frequency of ASFA 3 Category Therapeutic Plasmapheresis in Reanimation Intensive Care Units

    Acta Oncologica Turcica, 2019

    DOI 10.5505/aot.2019.54771 Open-access full textSource: OpenAlex

  35. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate

    Journal of Cancer Research and Therapeutics, 2018

    DOI 10.4103/0973-1482.192762 PMID 30488870 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  36. Vitamin B12 Level Have Prognostic Significance in Multiple Myeloma Patients

    AYBU AVESIS, 2018

    2 citations (OpenAlex) Source: OpenAlex

  37. Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.

    Turk patoloji dergisi, 2018

    DOI 10.5146/tjpath.2018.01430 PMID 29708579 7 citations (Europe PMC) Open-access full textSource: ORCID

  38. Association of initial prognostic parameters and requirement for treatment in chronic lymphocytic leukemia

    Leukemia Research, 2018

    Source: ORCID

  39. Factors associated with renal failure and renal function recovery in multiple myeloma

    Leukemia Research, 2018

    Source: ORCID

  40. Thiol-disulphide homeostasis in essential thrombocytemia patients

    Leukemia Research, 2018

    Source: ORCID

  41. Prevalence and current management of perianal diseases in patients with acute leukemia

    Ortadoğu Tıp Dergisi, 2018

    DOI 10.21601/ortadogutipdergisi.412212 Open-access full textSource: OpenAlex

  42. Importance of vitamin d level in early-stage chronic lymphocytic leukemia and its comparison with healthy population

    Medical Journal of Islamic World Academy of Sciences, 2018

    DOI 10.5505/ias.2018.67424 Open-access full textSource: OpenAlex

  43. Male sex and tumor diameter are independent risk factors for relapse or persistent disease in differentiated thyroid cancer

    Archives of the Balkan Medical Union, 2018

    DOI 10.31688/abmu.2018.53.3.11 Open-access full textSource: OpenAlex

  44. MULTİPLE MYELOM OLGULARINDA POLİNÖROPATİSIKLIĞI İLE KLİNİK VE LABORATUVAR BULGULARINKARŞILAŞTIRILMASI

    AYBU AVESIS, 2018

    Source: OpenAlex

  45. AKUT MYELOİD LÖSEMİ İNDÜKSİYON KEMOTERAPİSİNDEFUNGAL ENFEKSİYON SIKLIĞI İLE ANTİFUNGAL KULLANIMORANLARININ KARŞILAŞTIRILMASI

    AYBU AVESIS, 2018

    Source: OpenAlex

  46. MULTİPLE MYELOMA OLGULARINDA VÜCUT KİTLEİNDEKSİNİN PROGNOSTİK FAKTÖRLERE ETKİSİ

    AYBU AVESIS, 2018

    Source: OpenAlex

  47. Unexpected Adverse Effect of Cloforabin Plus Cytosine Arabinoside

    AYBU AVESIS, 2018

    Source: OpenAlex

  48. YOĞUN BAKIM ÜNİTESİNE BAŞVURAN HEMATOLOJİKKANSERLİ HASTALIKLAR VE PROGNOSTİK FAKTÖRLER

    AYBU AVESIS, 2018

    Source: OpenAlex

  49. THIOL – DISULPHIDE HOMEOSTASIS IN POLYCYTHEMIA VERA

    AYBU AVESIS, 2018

    Source: OpenAlex

  50. OTOLOG KÖK HÜCRE NAKLİ ADAYI MULTİPLE MYELOM OLGULARINDA VİNKRİSTİNDOKSORUBİSİN-DEKSAMETAZON KEMOTERAPİSİ İLE BORTEZOMİB İÇEREN REJİMLERİN RETROSPEKTİF OLARAK KARŞILAŞTIRILMASI

    AYBU AVESIS, 2018

    Source: OpenAlex